Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Smart Medical Journal OISAA Journal of Indonesia Emas
Yehuda Tri Nugroho Supranoto
Universitas Jember
Humanities Education Engineering Health Professions Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Public Health Social Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
ENHANCING THE POTENCIES OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T CELL) BY CRISPR/CAS9 SYSTEM TO ERADICATE RETINOBLASTOMA Yehuda Tri Nugroho Supranoto; Muhammad Yuda Nugraha; Astuti Setyawardani
Jurnal PPI Dunia Vol 3 No 2 (2020)
Publisher : OISAA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52162/jie.2020.003.02.5

Abstract

Retinoblastoma (RB) is the most common primary intraocular malignancy of childhood. There is no therapies that can eradicate specifically the whole cancer cells without any side effects. The disialoganglioside 2 (GD2), one of the cancer’s cell markers that can be treated using immunotherapy, is expressed in RB. Through this fact, immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells targeting cancer-specific antigens has shown great potential in treating this cancer. Although in recent studies show that immune cells are not able to destroy cancer cells because in every cancer cells there is protein programmed death ligand 1 (PD-L1). This literature review also shows the potential technology using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated protein (Cas9) method to silence PD-1 in CAR T cell, so PD-L1 can not deactivate CAR T Cell through PD-1 signaling. The combination using CAR T cell and CRISPR-Cas9 will be the great therapy to eradicate RB without any side effect.
Potensi Terapi Mesenchymal Stem Cells (MSCs) Untuk Gagal Hati Kronis Eksaserbasi Akut Akibat Infeksi Virus Hepatitis B: Tinjauan Sistematis dan Meta-analisis Terhadap Studi Uji Acak Terkontrol Yehuda Tri Nugroho Supranoto; Dini Cynthia Dewi Tanuwijaya
Smart Medical Journal Vol 4, No 3 (2021): Smart Medical Journal
Publisher : Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13057/smj.v4i3.54185

Abstract

Pendahuluan: Gagal hati kronis eksaserbasi akut merupakan dekompensasi penyakit hati kronis yang sering berkaitan dengan infeksi virus hepatitis B (HBV). Terapi Mesenchymal stem cells (MSCs) telah menunjukkan hasil yang menjanjikan untuk meningkatkan fungsi hati secara in vivo. Kajian ini bertujuan untuk menilai potensi MSCs pada pasien dengan gagal hati kronis eksaserbasi akut terkait infeksi HBV.Metode: Meta-analisis ini dibuat berdasarkan pedoman PRISMA. Pencarian literatur dilakukan dengan beberapa database elektronik, yakni PubMed, ScienceDirect, PMC, Google Scholar, dan Cochrane Library. Risk ratio (RR) dan standardized mean difference (SMD) dengan standar deviasi (SD) digunakan untuk membandingkan risiko mortalitas, skor model for end-stage liver disease (MELD), dan total bilirubin (TBIL) dari pemberian MSCs dan standard medical therapy (SMT).Hasil: Kajian ini menunjukkan bahwa risiko mortalitas cenderung lebih tinggi pada kelompok SMT (pooled RR= 0.52, 95%CI (0.40,0,69), p<0.00001, I2=0%). Skor MELD juga cenderung lebih tinggi pada kelompok SMT sampai 12 bulan setelah pengobatan (pooled SMD 0.36, 95%CI (0.07, 0.65), p= 0.00002, I2=65%). Perubahan TBIL lebih besar pada kelompok MSCs sampai dengan 4 minggu (pooled SMD= 0.20, 95%CI (-0.11,0.52), p=0.3, I2=16%) dan perubahan TBIL secara keseluruhan sampai 12 bulan menunjukkan adanya perbedaan antara intervensi MSCs dan SMT (pooled SMD= -0.07, 95%CI (-0.23,0.08), p=0.05, I2= 42%).Kesimpulan: Kajian ini memberikan bukti kuat yang menunjukkan terapi MSCs memiliki potensi yang bermanfaat untuk meningkatkan fungsi hati pada pasien dengan gagal hati kronis eksaserbasi akut terkait infeksi HBV.
Meta-Analysis of Enteral Lactoferrin Supplementation for Reducing the Risk of Preterm Infants Sepsis Yehuda Tri Nugroho Supranoto; Dini Cynthia Dewi Tanuwijaya
Smart Medical Journal Vol 5, No 2 (2022): Smart Medical Journal
Publisher : Faculty of Medicine Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13057/smj.v5i2.57007

Abstract

Introduction: Severe COVID-19 in pregnancy is strongly associated with preterm infant late-onset sepsis (LOS), which is a major cause of morbidity and mortality in infants. Recently, Lactoferrin, an iron-binding protein significantly discovered in human colostrum, shows potential effect on reducing the risk of preterm infant LOS and mortality by its immunomodulatory properties. Therefore, this study aimed to evaluate the effect of Lactoferrin on reducing the risk of preterm LOS, necrotizing enterocolitis (NEC), and mortality in preterm infants. Methods: This study followed the guidelines provided by PRISMA. A literature search was conducted with PubMed, Cochrane Library, Google Scholar, and ScienceDirect. The combined effect of LOS, NEC and mortality incidence were presented as risk ratios (RR) with a 95% confidence interval (CI) using a random-effects model (REM) or fixed-effects model (FEM) forest plot. Furthermore, the heterogeneity level was checked by I2 and the p-value of the chi2 test. Results: The incidence of LOS was significantly higher in the control than lactoferrin supplementation group [RR=0.65, 95% CI (0.56,0.77), p
Co-Authors Astuti Setyawardani Dini Cynthia Dewi Tanuwijaya Dini Cynthia Dewi Tanuwijaya Muhammad Yuda Nugraha